GSK has recently announced its exclusive license agreement with Hansoh Pharmaceutical Group for the innovative HS-20093 antibody-drug cancer treatment. This partnership includes substantial payments of up to $1.71 billion, contingent upon meeting specific milestones.
Initial Payment and Success-Based Milestones
As part of the agreement, GSK will make an upfront payment of $185 million to Hansoh. Additionally, the remaining payments will be tied to the achievement of success-based milestones for HS-20093.
Royalties and Global Sales
In anticipation of the commercialization of HS-20093, GSK has committed to paying tiered royalties on global net sales, excluding mainland China, Hong Kong, Macau, and Taiwan. This collaboration aims to make the treatment widely accessible to those in need.
Focus on Cancer Treatment Research
HS-20093 is currently undergoing multiple phase I and II clinical trials in China. The drug is being developed for the treatment of lung cancer, sarcoma, head and neck cancers, as well as other solid tumors. This research aligns with GSK’s dedication to advancing cancer therapies.
Positive Market Response
Following the announcement, GSK shares experienced a boost, with an increase of 13.60 pence or 0.95% at 1,446.40 pence as of 1248 GMT. Overall, GSK’s shares have shown a 0.6% increase year-to-date.